CO2022004594A2 - Oxinitruro de piridina, método para su preparación y uso de este - Google Patents

Oxinitruro de piridina, método para su preparación y uso de este

Info

Publication number
CO2022004594A2
CO2022004594A2 CONC2022/0004594A CO2022004594A CO2022004594A2 CO 2022004594 A2 CO2022004594 A2 CO 2022004594A2 CO 2022004594 A CO2022004594 A CO 2022004594A CO 2022004594 A2 CO2022004594 A2 CO 2022004594A2
Authority
CO
Colombia
Prior art keywords
preparation
present
oxynitride
pyridine
pyridine oxynitride
Prior art date
Application number
CONC2022/0004594A
Other languages
English (en)
Inventor
Qiong Zhang
Zhongli Wang
Ming Dai
Fengkai Cheng
Jiu Luo
Yan Ye
Jianbiao Peng
Haibing Guo
Original Assignee
Shanghai Jemincare Pharmaceuticals Co Ltd
Jiangxi Jemincare Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Jemincare Pharmaceuticals Co Ltd, Jiangxi Jemincare Group Co Ltd filed Critical Shanghai Jemincare Pharmaceuticals Co Ltd
Publication of CO2022004594A2 publication Critical patent/CO2022004594A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención pertenece al campo de la química médica. Se divulgan un oxinitruro de piridina, un método para su preparación y el uso de este. Específicamente, la presente invención se refiere a una serie de bloqueantes de los canales iónicos de sodio con una nueva estructura, un método para su preparación y el uso de estos. La estructura de estos es como se muestra en a continuación en la fórmula general (I). Los compuestos o un estereoisómero, un racemato, un isómero geométrico, un tautómero, un profármaco, un hidrato, un solvato o una sal farmacéuticamente aceptable de estos y una composición farmacéutica se puede utilizar para tratar o/y prevenir enfermedades relacionadas mediadas por un canal iónico de sodio (NaV).
CONC2022/0004594A 2019-09-12 2022-04-11 Oxinitruro de piridina, método para su preparación y uso de este CO2022004594A2 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201910863718 2019-09-12
CN201911094782 2019-11-11
CN202010531381 2020-06-11
CN202010923311 2020-09-04
PCT/CN2020/114700 WO2021047622A1 (zh) 2019-09-12 2020-09-11 吡啶氮氧化合物及其制备方法和用途

Publications (1)

Publication Number Publication Date
CO2022004594A2 true CO2022004594A2 (es) 2022-07-08

Family

ID=74866555

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0004594A CO2022004594A2 (es) 2019-09-12 2022-04-11 Oxinitruro de piridina, método para su preparación y uso de este

Country Status (15)

Country Link
US (1) US20230303495A9 (es)
EP (1) EP4043437A4 (es)
JP (1) JP2022548104A (es)
KR (1) KR20220101606A (es)
CN (2) CN113906013B (es)
AU (1) AU2020346951A1 (es)
BR (1) BR112022004495A8 (es)
CA (1) CA3150400A1 (es)
CL (1) CL2022000619A1 (es)
CO (1) CO2022004594A2 (es)
MX (1) MX2022003032A (es)
PE (1) PE20221515A1 (es)
TW (1) TWI770607B (es)
WO (1) WO2021047622A1 (es)
ZA (1) ZA202204100B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240019064A (ko) * 2021-03-11 2024-02-14 상하이 제민케어 파마슈티칼 컴퍼니 리미티드 피리딘 질소 산화물 화합물의 결정 형태 및 이의 용도
EP4347584A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
EP4346818A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
EP4347583A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
WO2022256622A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
EP4347033A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
WO2022256702A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
TW202340177A (zh) 2021-12-30 2023-10-16 美商拜歐米富士恩股份有限公司 作為 flt3抑制劑之吡嗪化合物
CN116891432A (zh) * 2022-04-02 2023-10-17 武汉人福创新药物研发中心有限公司 Nav1.8抑制剂及其用途
WO2023205468A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205465A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205778A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205463A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023232117A1 (zh) * 2022-06-02 2023-12-07 上海济煜医药科技有限公司 吡啶氮氧化合物的制备方法
WO2023246867A1 (zh) * 2022-06-22 2023-12-28 武汉人福创新药物研发中心有限公司 Nav1.8抑制剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69635254T2 (de) * 1995-07-07 2006-07-13 Astrazeneca Ab Ortho-substituierte aromatische Verbindungen, die drei (Het)aryl-Ringe enthalten, deren Herstellung und deren Verwendung als Prostaglandin-E2-(PGE2)-Antagonisten
EP1911751A4 (en) * 2005-06-21 2010-10-20 Mitsui Chemicals Agro Inc AMIDE DERIVATIVE AND PESTICIDE CONTAINING SUCH A COMPOUND
US8841483B2 (en) * 2006-04-11 2014-09-23 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of voltage-gated sodium channels
JP2010047480A (ja) * 2006-12-19 2010-03-04 Mitsui Chemicals Inc 虫害の予防方法
JP5436434B2 (ja) * 2007-10-11 2014-03-05 バーテックス ファーマシューティカルズ インコーポレイテッド 電位開口型ナトリウムチャネルの阻害剤として有用なアミド
JP5562859B2 (ja) * 2007-10-11 2014-07-30 バーテックス ファーマシューティカルズ インコーポレイテッド 電位開口型ナトリウムチャネルの阻害剤として有用なアリールアミド
AU2011346751A1 (en) * 2010-12-22 2013-05-02 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
CN105073738B (zh) * 2013-01-31 2018-01-05 沃泰克斯药物股份有限公司 作为钠通道调节剂的喹啉及喹喔啉酰胺类
KR102295748B1 (ko) * 2013-01-31 2021-09-01 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 피리돈 아미드
WO2014120820A1 (en) * 2013-01-31 2014-08-07 Vertex Pharmaceuticals Incorporated Amides as modulators of sodium channels
LT3080134T (lt) * 2013-12-13 2018-11-12 Vertex Pharmaceuticals Incorporated Piridono amidų provaistai, naudotini kaip natrio kanalų moduliatoriai
MA49566A (fr) * 2017-07-11 2020-05-20 Vertex Pharma Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques
EP3820866A4 (en) * 2018-07-09 2022-04-06 Lieber Institute, Inc. PYRIDINE CARBOXAMIDE COMPOUNDS TO INHIBIT NAV1.8

Also Published As

Publication number Publication date
CN112479996B (zh) 2023-05-26
KR20220101606A (ko) 2022-07-19
TWI770607B (zh) 2022-07-11
CN113906013A (zh) 2022-01-07
CA3150400A1 (en) 2021-03-18
CN112479996A (zh) 2021-03-12
JP2022548104A (ja) 2022-11-16
PE20221515A1 (es) 2022-10-04
BR112022004495A8 (pt) 2023-04-18
US20230026907A1 (en) 2023-01-26
CN113906013B (zh) 2024-03-12
WO2021047622A1 (zh) 2021-03-18
BR112022004495A2 (pt) 2022-05-31
US20230303495A9 (en) 2023-09-28
EP4043437A1 (en) 2022-08-17
ZA202204100B (en) 2024-04-24
MX2022003032A (es) 2022-07-12
EP4043437A4 (en) 2023-10-04
AU2020346951A1 (en) 2022-04-28
CL2022000619A1 (es) 2022-10-28
TW202114990A (zh) 2021-04-16

Similar Documents

Publication Publication Date Title
CO2022004594A2 (es) Oxinitruro de piridina, método para su preparación y uso de este
NI201400031A (es) Derivados de ( 4 - fenilimidazol - 2 - il ) etilamina útiles como moduladores de canal de sodio
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
EA201790389A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
PE20181778A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue
EA201791955A1 (ru) ИНГИБИТОРЫ TGF-β
EA201390401A1 (ru) ПИРАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ENaC БЛОКАТОРОВ
CL2013002690A1 (es) Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona, inhibidores de notch; compuesto cristalino; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del cancer.
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201791941A1 (ru) Бициклические кетосульфонамидные соединения
EA201592144A1 (ru) Производное фенола, способ его получения и его применение в медицине
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
EA201600337A1 (ru) 2,6-замещенные пуриновые производные и их применение в лечении пролиферативных заболеваний
CL2017002957A1 (es) Benzamidas sustituidas y métodos para utilizarlas
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
MX2020003993A (es) Derivados de bencimidazol y sus usos.
EA202192905A1 (ru) Соединения, содержащие n-метил-2-пиридон, и фармацевтически приемлемые соли
EA202091604A1 (ru) Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом
AR089122A1 (es) Formulaciones orales para tratar la sobrecarga de metales
CO2018007436A2 (es) Compuestos de dihidroquinolinsulfonamida de alquilo
PH12018500469A1 (en) Sulfonamide compounds as voltage-gated sodium channel modulators
BR112022012684A2 (pt) Compostos cíclicos e métodos de uso dos mesmos
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer